Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab as Consolidation Therapy for CLL/SLL
NCT07108998Phase 2Recruiting
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Primary endpoint: Undetectable Minimal Residual Disease Complete Response at 336 days. Started Aug 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07108998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108998.